Cart
sales@molnova.com
SU-9516
CAS No. 377090-84-1
SU-9516 ( SU9516;SU 9516 )
Catalog No. M14301 CAS No. 377090-84-1
A selective CDK2 inhibitor with IC50 of 22 nM; shows less potent for CDK1/CDK4(IC50=40/200 nM), no inhibition on PKC, EGFR, p38MAPK; decreases the phosphorylation of pRb, and increases caspase-3 activation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 39 | In Stock |
|
| 5MG | 60 | In Stock |
|
| 10MG | 95 | In Stock |
|
| 25MG | 197 | In Stock |
|
| 50MG | 356 | In Stock |
|
| 100MG | 530 | In Stock |
|
| 500MG | 1152 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU-9516
-
NoteResearch use only, not for human use.
-
Brief DescriptionA selective CDK2 inhibitor with IC50 of 22 nM; shows less potent for CDK1/CDK4(IC50=40/200 nM), no inhibition on PKC, EGFR, p38MAPK; decreases the phosphorylation of pRb, and increases caspase-3 activation.
-
DescriptionA selective CDK2 inhibitor with IC50 of 22 nM; shows less potent for CDK1/CDK4(IC50=40/200 nM), no inhibition on PKC, EGFR, p38MAPK; decreases the phosphorylation of pRb, and increases caspase-3 activation.
-
SynonymsSU9516;SU 9516
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK1;CDK2;CDK4;p38;PKC
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number377090-84-1
-
Formula Weight241.25
-
Molecular FormulaC13H11N3O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C1NC2=C(C=C(OC)C=C2)/C1=C/C3=CN=CN3
-
Chemical Name2H-Indol-2-one, 1,3-dihydro-3-(1H-imidazol-5-ylmethylene)-5-methoxy-, (3Z)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lane ME, et al. Cancer Res. 2001 Aug 15;61(16):6170-7.
2. Gao N, et al. Mol Pharmacol. 2006 Aug;70(2):645-55.
3. Sarathy A, et al. Mol Ther. 2017 Apr 5. pii: S1525-0016(17)30121-1.
2. Gao N, et al. Mol Pharmacol. 2006 Aug;70(2):645-55.
3. Sarathy A, et al. Mol Ther. 2017 Apr 5. pii: S1525-0016(17)30121-1.
molnova catalog
related products
-
VMY-1-103
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
-
G1T38
G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
-
CDK9-IN-1
CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
